<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302064</url>
  </required_header>
  <id_info>
    <org_study_id>ION-682884-CS20</org_study_id>
    <nct_id>NCT04302064</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of AKCEA-TTR-LRx in Healthy Japanese Participants</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of ION-682884 in Healthy Japanese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of single and potentially multiple doses of&#xD;
      AKCEA-TTR-LRx administered subcutaneously (SC) to healthy Japanese participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, double-blinded, placebo-controlled study in up to 44 participants.&#xD;
      Participants will be randomized to receive three subcutaneous single-ascending doses and&#xD;
      potentially multiple doses of AKCEA-TTR-LRx or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2020</start_date>
  <completion_date type="Actual">September 10, 2020</completion_date>
  <primary_completion_date type="Actual">September 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity</measure>
    <time_frame>Up to 92 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with TEAEs Potentially Related to Study Drug</measure>
    <time_frame>Up to 92 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Changes in Clinically Significant (CS) Laboratory Value Abnormalities</measure>
    <time_frame>Up to 92 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>AKCEA-TTR-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of AKCEA-TTR-LRx administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose on Day 1 or multiple doses (every 4 weeks for 12 weeks) of AKCEA-TTR-LRx-matching placebo administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKCEA-TTR-LRx</intervention_name>
    <description>AKCEA-TTR-LRx administered SC</description>
    <arm_group_label>AKCEA-TTR-LRx</arm_group_label>
    <other_name>ION-682884</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>AKCEA-TTR-LRx-matching placebo administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Must have given written informed consent (signed and dated) and any authorizations&#xD;
             required by local law and be able to comply with all study requirements&#xD;
&#xD;
          2. Healthy Japanese males or females of non-childbearing potential, aged 20 to 65&#xD;
             inclusive at the time of informed consent defined as being of first- or&#xD;
             second-generation ethnic origin with each set of parents qualifying as Japanese under&#xD;
             the prior generation. Generations will be defined as follows:&#xD;
&#xD;
               -  First generation Japanese participants must be born in Japan, cannot have lived&#xD;
                  outside of Japan for more than 10 years, must maintain Japanese diet, culture and&#xD;
                  lifestyle and parents and both sets of grandparents are of Japanese origin&#xD;
&#xD;
               -  Second-generation Japanese are participants who are born outside of Japan to the&#xD;
                  first-generation Japanese parents&#xD;
&#xD;
          3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g.,&#xD;
             tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or&#xD;
             post-menopausal (defined as 12 months of spontaneous amenorrhea without an alternative&#xD;
             medical cause and follicle-stimulating hormone (FSH) levels in the postmenopausal&#xD;
             range for the laboratory involved Males must be surgically sterile or abstinent*, if&#xD;
             engaged in sexual relations with a female of child-bearing potential, the participant&#xD;
             must be using an acceptable contraceptive method from the time of signing the informed&#xD;
             consent form until at least 91 days (single-dose cohorts) or 13 weeks (multiple-dose&#xD;
             cohorts) after the last dose of Study Drug (AKCEA-TTR-LRx or placebo)&#xD;
&#xD;
             * Abstinence is only acceptable as true abstinence, i.e., when this is in line with&#xD;
             the preferred and usual lifestyle of the participant. Periodic abstinence (e.g.,&#xD;
             calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence&#xD;
             for the duration of a trial and withdrawal are not acceptable methods of&#xD;
             contraception.&#xD;
&#xD;
          4. Willingness to take vitamin A supplements&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Clinically significant abnormalities in medical history (e.g., previous acute coronary&#xD;
             syndrome within 6 months of Screening, major surgery within 3 months of Screening) or&#xD;
             physical examination&#xD;
&#xD;
          2. Screening laboratory results as follows, or any other clinically significant&#xD;
             abnormalities in Screening laboratory values that would render a participant&#xD;
             unsuitable for inclusion&#xD;
&#xD;
               -  Random spot urine protein/creatinine (P/C) ratio (UPCR) â‰¥ 200 milligrams per gram&#xD;
                  (mg/g).&#xD;
&#xD;
               -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin,&#xD;
                  alkaline phosphatase (ALP), serum creatinine, blood urea nitrogen (BUN) &gt; upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  Fasting blood glucose &gt; ULN&#xD;
&#xD;
               -  Platelet count &lt; lower limit of normal (LLN)&#xD;
&#xD;
          3. Uncontrolled hypertension (blood pressure [BP] &gt; 160/100 millimeters of mercury [mm&#xD;
             Hg])&#xD;
&#xD;
          4. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix that has been successfully treated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

